Splits Over Data Protection Could Hamper EU Pharma Revision
The chances of reaching agreement on proposals to overhaul the EU pharma rules before the European Parliament elections in June 2024 are receding as disagreements emerge over key issues such as regulatory data protection and how to encourage antimicrobial R&D.
You may also be interested in...
A second public consultation on the review of the HTA system will be held in January to February 2024 after more than 100 stakeholder responses were received during the first consultation earlier this year.
Low- and middle-income countries need to have the know-how, capability and capacity to produce mRNA vaccines, from concept, design and testing through to manufacturing and registration, a conference heard this week.
On the back of a successful pilot of early consultations with patients, the European Medicines Agency is extending the initiative so that patient and health care professional groups can give valuable input in areas such as unmet needs, clinical trial endpoints and expectations for future treatments.